GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (XAMS:GLPG) » Definitions » Accounts Payable & Accrued Expense

Galapagos NV (XAMS:GLPG) Accounts Payable & Accrued Expense : €169.1 Mil (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Accounts Payable & Accrued Expense?

Galapagos NV's quarterly accounts payable & accrued expense declined from Sep. 2024 (€116.1 Mil) to Dec. 2024 (€99.1 Mil) but then increased from Dec. 2024 (€99.1 Mil) to Mar. 2025 (€169.1 Mil).

Galapagos NV's annual accounts payable & accrued expense declined from Dec. 2022 (€141.2 Mil) to Dec. 2023 (€135.3 Mil) and declined from Dec. 2023 (€135.3 Mil) to Dec. 2024 (€99.1 Mil).

Galapagos NV Accounts Payable & Accrued Expense Historical Data

The historical data trend for Galapagos NV's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Accounts Payable & Accrued Expense Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.63 139.20 141.19 135.26 99.12

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.61 128.45 116.07 99.12 169.14

Galapagos NV Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Galapagos NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (XAMS:GLPG) » Definitions » Accounts Payable & Accrued Expense
Comparable Companies
XAMS:PHARM XAMS:VVY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392
Traded in Other Exchanges
GLPGF:USA GLPG:USA GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil GLPG:Austria
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Website
https://www.glpg.com
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.